الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 164 |  |  |
| | | from | 164 | | |
Abstract
The results of RIPCORD 2 study were at the time of writing, yet to be formally presented due to delays in follow up related to COVID-19 pandemic. The results presented in this thesis are related to the 215 patients who were recruited by Liverpool Heart and Chest Hospital due to their presentation by either stable angina or ACS and were randomized in equal proportion to either angiography only (n=109) or additional FFR (n=106), so these results are considered only a representative sample of how we used the EQ5D5L questionnaire and the HES to derive our outcomes and are not the final results of the trial. The two arms of the study were well balanced in terms of their baseline characteristics including; demographic characteristics, risk factors, & presentation. In terms of the procedure related data, our results showed that the procedure time & contrast dose that were added by FFR recording were statistically significantly different when compared to the conventional angiography (P< 0.001). The mean number (± SD) of vessels examined by FFR was (3.9 ±1.1). Additionally, the percentages of patients with 2 & 3 vessel disease were higher in the FFR group (32.1%) versus (23.8%) in the angiography group. Regarding the final management plan, our results revealed that 17.4% of the patients who had angiography only required additional non-invasive tests before the declaration of the final management plan versus 3.7% in the patient who had additional FFR in the same procedure. Additionally, it was shown that there was no statistical difference between the two groups regarding the percentage of patients whose management plan was declared to